•
Jun 30, 2020
Agenus Q2 2020 Earnings Report
Agenus reported financial results and provided an R&D and business update.
Key Takeaways
Agenus reported a net loss of $48 million, or $0.28 per share, for the second quarter of 2020. The company's cash balance at the end of the quarter was $79 million. Agenus recognized revenue of $26.945 million for the quarter.
Ended the second quarter of 2020 with a cash balance of $79 million.
Net loss for the second quarter ended June 30, 2020 was $48 million or $0.28 per share.
Completed partnership with Betta Pharmaceuticals with $35M in cash and equity received.
Balstilimab BLA filing to be initiated in current quarter.
Agenus
Agenus
Agenus Revenue by Segment
Forward Guidance
Based on current plans and projections, Agenus' cash position will be sufficient to support operations into the third quarter of 2021.